Sign in
4

Changes in Ownership

Prelude Therapeutics Inc Filed Acc 0001562180-23-001169

Options or other derivatives

  • EVP, Head of Chemistry acquired 135,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Combs Andrew · EVP, Head of Chemistry

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-02-07 Grant or award : show line 1 in the form Employee Stock Option (right to buy) +135,000 135,000 D
Loading xslF345X03/primarydocument.xml…